Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

CATALYST PHARMACEUTICALS, INC. Director's Dealing 2023

Dec 29, 2023

31542_dirs_2023-12-29_c2a7af52-1b19-4a21-bfd3-e0608702d66f.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CATALYST PHARMACEUTICALS, INC. (CPRX)
CIK: 0001369568
Period of Report: 2023-12-27

Reporting Person: GRANDE ALICIA (VP, Treasurer and CFO)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2023-12-27 Common Stock, par value $0.001 per share M 8666 Acquired 59223 Direct
2023-12-27 Common Stock, par value $0.001 per share F 3410 Disposed 55813 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2023-12-27 Restricted Stock Units $ M 8666 Disposed Common Stock (8666) Direct

Footnotes

F1: Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting.

F2: Shares withheld by the Registrant to satisfy applicable withholding taxes upon vesting of restricted stock units.

F3: Derivative securities vest in equal tranches, 1/3rd on December 27, 2023, 1/3rd on December 27, 2024 and 1/3rd on December 27, 2025.

F4: Shares of common stock are required to be delivered to the Reporting Person within sixty days of vesting. The first tranche of shares was delivered on December 27, 2023.